MedTrace Logo

Prospective, Randomized, Controlled, Clinical Study on Tolerability and Efficacy of hMG-IBSA

NCT00464607 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2007-04-23

No results posted yet for this study

Summary

Purpose of the study is the evaluation of the tolerability (both local and systemic) and the clinical efficacy (in terms oocytes recovered) of subcutaneously versus intramuscularly administered Merional® (IBSA, Lugano - CH) in patients undergoing controlled ovarian hyperstimulation (COH) in an ART programme (IVF).

Conditions

Interventions

DRUG

hMG-IBSA

PROCEDURE

Ovarian stimulation

Sponsors & Collaborators

  • IBSA Institut Biochimique SA

    lead INDUSTRY

Principal Investigators

  • Nicola Ragni, Prof. · Ospedale S.Martino - Genova (Italy)

  • Luigi Fedele, Prof. · Ospedale S. Paolo - Milano (Italy)

  • Giuseppe De Placido, Prof. · Ospedale Federico II - Napoli (Italy)

  • Marco Massobrio, Prof. · Ospedale S. Anna - Torino (Italy)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-12-31
Completion
2005-04-30

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00464607 on ClinicalTrials.gov